hrp0098p2-296 | Late Breaking | ESPE2024

Treatment with Continuous Subcutaneous Hydrocortisone Infusion (CHSI) in Children with congenital adrenal hyperplasia (CAH) due to 21 hydroxylase deficiency: An Option for Poorly Controlled Patients

Sophie Lambert Anne , Agathe Trouvin Marie , Reguieg Khadidja , Rothenbuhler Anya , Teinturier Cecile , Linglart Agnes , Bouvattier Claire

Introduction: Children with CAH need a supraphysiologic dose of hydrocortisone, from 12-20 mg/m2/day to suppress adrenal androgens. Patients with difficult-to-treat CAH typically present with a combination of CAH-related (hyperandrogenemia, advancedbone age and short stature, amenorrhea) and glucocorticoid overtreatment–related clinical symptoms. Continuous subcutaneous hydrocortisone infusion therapy (CSHI) administered via an insulin pump has been used...